Výsledky vyhledávání - "Garry, Schwartz"

A case study of 10 patients administered HBOC‐201 in high doses over a prolonged period: outcomes during severe anemia when transfusion is not an option

Autor: Garry Schwartz, Mauricio Lynn, Kim Hien T. Dao, Katherine Walsh, Jed B. Gorlin, Marc Zumberg, Amanda M. VanSandt, Elizabeth A. Griffiths, Aryeh Shander, Bradley S. Fletcher

Publikováno v: Transfusion. 60:932-939

BACKGROUND Hemoglobin-Based Oxygen Carriers (HBOCs) can act as an "oxygen bridge" in acute severe anemia when transfusion is indicated, but not possible. We present data on 10 Expanded Access (EA) patients treated with high cumulative doses of Hemopu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::326301ae90360dc606ba4659eac97ff2
https://doi.org/10.1111/trf.15778

Zobrazit plný text záznamu

Use of the blood substitute HBOC-201 in critically ill patients during sickle crisis: a three-case series

Autor: Ernest DiNino, Mark Tidswell, Garry Schwartz, Nura El-Haj, Margaret Block, Nimish Shah, James Wall, Jonathan M. Davis

Publikováno v: Transfusion. 58:132-137

BACKGROUND Red blood cell (RBC) transfusion is an important treatment modality during severe sickle cell crisis (SCC). SCC patients who refuse, or cannot accept, RBCs present a unique challenge. Acellular hemoglobin (Hb)-based oxygen carriers (HBOCs)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::93c3aed51365380aa214ad5ab73593da
https://doi.org/10.1111/trf.14386

Zobrazit plný text záznamu

In vivoassessment of the metabolic activity of CYP2D6 diplotypes and alleles

Publikováno v: British Journal of Clinical Pharmacology. 80:1122-1130

Aims A prospectively enrolled patient cohort was used to assess whether the prediction of CYP2D6 phenotype activity from genotype data could be improved by reclassification of diplotypes or alleles. Methods Three hundred and fifty-five patients recei

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::06094b83820dbacca61d5d9591033ea6
https://doi.org/10.1111/bcp.12665

Zobrazit plný text záznamu

Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non–Small-Cell Lung Cancer: Results of a Phase I/II Trial

Autor: Dominic T. Moore, Garry Schwartz, David E. Morris, A. William Blackstock, Scott N. Gettinger, Roy H. Decker, W. Jeffrey Petty, Scott P. Lankford, Thomas E. Stinchcombe, Amir H. Khandani, Mark A. Socinski

Publikováno v: Journal of Clinical Oncology. 30:3953-3959

Purpose Bevacizumab and erlotinib have been shown to improve survival in stage IV non–small-cell lung cancer (NSCLC). This phase I/II trial was designed to incorporate these agents with induction and concurrent chemoradiotherapy in stage III NSCLC.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cf0dae56f4074f15318e836079b3f62
https://doi.org/10.1200/jco.2012.41.9820

Zobrazit plný text záznamu

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

Autor: Kenneth K. Iwata, Bret Wacker, Monica M. Mita, Q S-C Chu, K Witt, Leslie Wood, Eric K. Rowinsky, S McCarthy, A. Ricart, Alain C. Mita, Garry Schwartz, M.J.A. de Jonge, Jaap Verweij, Kyriakos P. Papadopoulos, Anthony W. Tolcher, M. Hamilton

Publikováno v: British Journal of Cancer, 105(7), 938-944. Nature Publishing Group
British Journal of Cancer

BACKGROUND: To evaluate the anticancer activity of erlotinib in patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose dose is increased to that associated with a maximal level of tolerable skin toxicity (i.e., target ras

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::481abfa49e01148b797e2c3145ea45a4
https://doi.org/10.1038/bjc.2011.332

Zobrazit plný text záznamu

Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

Autor: Kyle D. Holen, Glenn Liu, George Wilding, Geoffrey R. Weiss, Anthony W. Tolcher, A. Ricart, Garry Schwartz, Chee Ng, Mark R. Albertini, Salim Yazji

Publikováno v: Clinical Cancer Research. 14:7924-7929

Purpose: This study aimed to assess the safety and feasibility of administering volociximab, a chimeric monoclonal antibody that specifically binds to α5β1 integrin, and to determine the pharmacokinetics, pharmacodynamics, and preliminary evidence

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33ab857e34c358c5c9b2bb5773f789f7
https://doi.org/10.1158/1078-0432.ccr-08-0378

Zobrazit plný text záznamu

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Autor: Martin E. Gleave, Elzbieta Izbicka, Kim N. Chi, Garry Schwartz, Ian M. Thompson, Chris H. Takimoto, Nevin Murray, Anthony W. Tolcher, Stanley R. Frankel, John G. Kuhn, Eric K. Rowinsky, Amita Patnaik, Susan D’Aloisio, K. Berg

Publikováno v: Clinical Cancer Research. 11:3854-3861

Purpose: To determine the antitumor activity and safety of oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the bcl-2 mRNA, with docetaxel in patients with hormone-refractory prostate cancer (HRPC) and to determine if relev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38498319574e89408153543a0cc6975c
https://doi.org/10.1158/1078-0432.ccr-04-2145

Zobrazit plný text záznamu

A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties

Autor: Jinee Rizzo, John G. Kuhn, Lisa A. Hammond, Garry Schwartz, Anthony W. Tolcher, Manuel Hidalgo, Eric K. Rowinsky, Amita Patnaik, S. Gail Eckhardt, Chris H. Takimoto, Samira Syed

Publikováno v: Clinical Cancer Research. 10:6512-6521

Purpose: The purpose of this research was to assess the feasibility of administering Col-3, an oral chemically modified tetracycline derivative with potent inhibitory effects on matrix metalloproteinase activity and production, and recommend a dose o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d18cf66acaf310c3c17a4855fa1bcb44
https://doi.org/10.1158/1078-0432.ccr-04-0804

Zobrazit plný text záznamu

Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer

Autor: John A. Thompson, Naomi B. Haas, Jared A. Gollob, Garry Schwartz, Eric K. Rowinsky, Nicholas J. Vogelzang, Robert A. Figlin, Rosalin H. Arends, Kenneth A. Foon, Yu Ping Li, Pamela Lockbaum, Ronald M. Bukowski, Gisela Schwab, Janice P. Dutcher

Publikováno v: Journal of Clinical Oncology. 22:3003-3015

PurposeTo determine the antitumor activity of ABX-EGF, a fully human monoclonal antibody to the epidermal growth factor receptor (EGFr), in previously treated patients with metastatic renal cell carcinoma, and to characterize its toxicity, immunogeni

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77e63a55851c819ef678abe0afddf82f
https://doi.org/10.1200/jco.2004.11.061

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání